EICHORPublic-registry site landscape for NCT07700667, “SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma”, a Esophageal Squamous Cell Carcinoma study sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07700667 (registry record) |
| Study title | SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma |
| Official title | A Phase II, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma |
| Sponsor | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
| Condition(s) | Esophageal Squamous Cell Carcinoma |
| Phase | PHASE2 |
| Listed sites | 23 |
| Intervention(s) | SKB500, Tislelizumab, Cisplatin, 5 - FU |
| Site countries | China |
Patient-friendly overview of this study: eichor.com/study/NCT07700667.
Eichor generates a preliminary site-risk snapshot for NCT07700667 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
